Pharming Group Overview

  • Founded
  • 1988
Founded
  • Status
  • Public
  • Employees
  • 229
Employees
  • Stock Symbol
  • PHARM
Stock Symbol
  • Investments
  • 7
  • Share Price
  • $1.12
  • (As of Wednesday Closing)

Pharming Group General Information

Description

Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on the development and production of human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. Most of the revenue is generated from the United States.

Contact Information

Website
www.pharming.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Other Commercial Services
Biotechnology
Stock Exchange
AMS
Primary Office
  • Darwinweg 24
  • 2333 CR Leiden
  • Netherlands
+31 071 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Pharming Group Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.12 $1.11 $0.99 - $1.83 $713M 639M 4.65M $0.06

Pharming Group Financials Summary

In Thousands,
USD 		TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 797,085 969,182 1,096,318 536,802
Revenue 200,899 211,675 189,211 159,462
EBITDA 45,667 57,270 71,079 20,999
Net Income 36,884 37,657 40,518 29,493
Total Assets 408,566 419,121 255,634 245,347
Total Debt 153,605 162,218 58,136 83,424
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pharming Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pharming Group‘s full profile, request access.

Request a free trial

Pharming Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses o
Pharmaceuticals
Leiden, Netherlands
229 As of 2020
00000
000000000 00000

000000

abore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nis
000000000000000
Loos, France
000 As of 0000
00000
000000000. 0 00000

000000 0

agna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex e
0000000000000
Oxford, United Kingdom
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pharming Group Competitors (28)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genfit Formerly VC-backed Loos, France 000 00000 000000000. 0 00000
000000 000000000 Corporation Oxford, United Kingdom 000 00000 00000000000 00000
000000 00000000 Formerly VC-backed Taipei, Taiwan 000 000.00 000000000 000.00
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
00000000 Formerly VC-backed South San Francisco, CA 00 00000 0000000000.
You’re viewing 5 of 28 competitors. Get the full list »

Pharming Group Executive Team (14)

Name Title Board Seat Contact Info
Sijmen de Vries MD Chief Executive Officer & Chairman
Jeroen Wakkerman Chief Financial Officer, Finance
Mireille Sanders Chief Operating Officer, Operations
James Cornicelli Vice President, Global Business Development
A. De Winter Chairman of the Audit Committee and member of the Corporate Governance Committee
You’re viewing 5 of 14 executive team members. Get the full list »

Pharming Group Board Members (11)

Name Representing Role Since
A. De Winter Pharming Group Chairman of the Audit Committee and member of the Corporate Governance Committee 000 0000
Deborah Jorn Pharming Group Vice-Chairwoman of the Board of Directors, Member of the Audit Committee and Chairwoman of the Remuneration Committee 000 0000
J.B. Ward Ph.D Pharming Group Chairman of the Corporate Governance Committee 000 0000
J.H.L. Ernst Pharming Group Vice Chairman of the Board of Supervisory Directors, and a member of the Audit and Remuneration Committee 000 0000
Mark Pykett Ph.D Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Pharming Group Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pharming Group Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Pharming Group‘s full profile, request access.

Request a free trial

Pharming Group Investments & Acquisitions (7)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 00000 (00 01-Jan-2020 000000000 00000 00 Buildings and Property
00000000 (00000000 13-Aug-2019 000000000 00000 00 0000 Buildings and Property
0000000000000 09-Apr-2019 000000000 00.000 Pharmaceuticals 000000 00 00000 00
0000000000000 09-Apr-2019 000000000 00000000 Pharmaceuticals 000000 00 00000 00
Ruconest (North American commercialization rights) 08-Dec-2016 Corporate Asset Purchase 00000 Buildings and Property
You’re viewing 5 of 7 investments and acquisitions. Get the full list »

Pharming Group Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000 23-Mar-2006 000000000000000000 Completed
  • 00000000 00000
To view Pharming Group’s complete exits history, request access »